The SARS-CoV-2 pandemic continues despite the presence of effective vaccines, and novel vaccine approaches may help to reduce viral spread and associated COVID-19 disease. Current vaccine administration modalities are based on systemic needle-administered immunisation which may be suboptimal for mucosal pathogens. Here we demonstrate in a mouse model that small-volume intranasal administration of purified spike (S) protein in the adjuvant polyethylenemine (PEI) elicits robust antibody responses with modest systemic neutralisation activity. Further, we test a heterologous intranasal immunisation regimen, priming with S and boosting with RBD-Fc. Our data identify small volume PEI adjuvantation as a novel platform with potential for protective mucosal vaccine development.
Journal article
2022-12-01T00:00:00+00:00
511
Adaptive immunity, COVID-19, Mucosal adjuvant, RBD, SARS-CoV-2, Spike, Vaccine, Mice, Animals, Administration, Intranasal, SARS-CoV-2, Polyethyleneimine, COVID-19, Vaccines